Menu
Search
|

Menu

Close
X

Kura Oncology Inc KURA.OQ (NASDAQ Stock Exchange Global Select Market)

20.10 USD
-0.30 (-1.47%)
As of Jul 20
chart
Previous Close 20.40
Open 20.40
Volume 30,328
3m Avg Volume 83,544
Today’s High 20.55
Today’s Low 19.95
52 Week High 24.00
52 Week Low 5.90
Shares Outstanding (mil) 36.86
Market Capitalization (mil) 751.87
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.33 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.459
FY17
-1.532
FY16
-1.473
FY15
-1.281
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.05
Price to Sales (TTM)
vs sector
--
8.10
Price to Book (MRQ)
vs sector
5.29
4.20
Price to Cash Flow (TTM)
vs sector
--
22.23
Total Debt to Equity (MRQ)
vs sector
5.73
17.32
LT Debt to Equity (MRQ)
vs sector
3.90
13.18
Return on Investment (TTM)
vs sector
-45.24
13.17
Return on Equity (TTM)
vs sector
-48.57
15.10

EXECUTIVE LEADERSHIP

Troy Wilson
Chairman of the Board, President, Chief Executive Officer, Principal Financial Officer, Principal Accounting Officer, Since 2018
Salary: $82,500.00
Bonus: --
John Farnam
Chief Operating Officer, Since 2018
Salary: --
Bonus: --
Annette North
Senior Vice President, General Counsel, Since 2015
Salary: --
Bonus: --
Pingda Ren
Senior Vice President - Chemistry and Pharmaceutical Sciences, Since 2014
Salary: --
Bonus: --
Liu Yi
Chief Scientific Officer, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

3033 Science Park Rd Ste 220
SAN DIEGO   CA   92121-1166

Phone: +1858.5008800

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule product candidates that targets cell-signaling pathways, which drives the progression of certain cancers. It is developing its lead product candidate, tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with tumors that have mutations in or other dysregulation of the mitogen-activated protein kinase (MAPK), signaling pathway, including pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma.

SPONSORED STORIES